Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (191-200 of 377) with videos related to

Pageof 38
Sort By:
Breast Cancer Research and Treatment|September 7, 2017
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trialsMarion T van Mackelenbergh, Carsten Denkert, Valentina Nekljudova, et al.
Breast Cancer Research and Treatment|March 19, 2017
Efficacy and safety of nab-paclitaxel 125 mg/m<sup>2</sup> and nab-paclitaxel 150 mg/m<sup>2</sup> compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)Jenny Furlanetto, Christian Jackisch, Michael Untch, et al.
International Journal of Cancer|April 20, 2004
Limited relevance of the CHEK2 gene in hereditary breast cancerMichael R Dufault, Beate Betz, Barbara Wappenschmidt, et al.
JAMA Oncology|May 19, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical TrialJens-Uwe Blohmer, Theresa Link, Mattea Reinisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyMichael Untch, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro studyGunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE TrialPeter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
The New England Journal of Medicine|February 27, 2020
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Lajos Pusztai, et al.
Geburtshilfe Und Frauenheilkunde|April 19, 2021
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer PatientsMichael P Lux, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Pageof 38

Showing results (191-200 of 377) with videos related to

Sort By:
Pageof 38
Breast Cancer Research and Treatment|September 7, 2017
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trialsMarion T van Mackelenbergh, Carsten Denkert, Valentina Nekljudova, et al.
Breast Cancer Research and Treatment|March 19, 2017
Efficacy and safety of nab-paclitaxel 125 mg/m<sup>2</sup> and nab-paclitaxel 150 mg/m<sup>2</sup> compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)Jenny Furlanetto, Christian Jackisch, Michael Untch, et al.
International Journal of Cancer|April 20, 2004
Limited relevance of the CHEK2 gene in hereditary breast cancerMichael R Dufault, Beate Betz, Barbara Wappenschmidt, et al.
JAMA Oncology|May 19, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical TrialJens-Uwe Blohmer, Theresa Link, Mattea Reinisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyMichael Untch, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro studyGunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE TrialPeter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
The New England Journal of Medicine|February 27, 2020
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Lajos Pusztai, et al.
Geburtshilfe Und Frauenheilkunde|April 19, 2021
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer PatientsMichael P Lux, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Pageof 38